Stemline Therapeutics (STML) Files $50M IPO
Tweet
Share
E-mailGet Alerts STML Hot Sheet
Join SI Premium – FREE
In a Form S-1 late Monday, Stemline Therapeutics (Nasdaq: STML) registered a $50 million initial public offering. The company plans to list on the NASDAQ under the symbol "STML."
The offering is being made through Oppenheimer and JMP Securities.
Stemline is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing proprietary therapeutics that target both cancer stem cells, or CSCs, and tumor bulk.
The offering is being made through Oppenheimer and JMP Securities.
Stemline is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing proprietary therapeutics that target both cancer stem cells, or CSCs, and tumor bulk.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rectitude Holdings (RECT) Announces 2M Share IPO at $4-$6/sh
- SOPHiA GENETICS (SOPH) Announces Syndicate Bio as First Liquid Biopsy Customer in Africa
- Chinese bubble tea company Chabaidao sees shares tumble in Hong Kong market debut
Create E-mail Alert Related Categories
IPOsRelated Entities
JMP Securities, S1Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
